Table 2.
Landscape of Emerging Allele-Specific Targeted Regimens for Mutant mPDAC at ASCO 2026
| Study/Abstract | Target/Population | Experimental Regimen | Key Clinical/Safety Findings |
|---|---|---|---|
| Abstract #3007 |
KRAS G12D Advanced solid tumors (66.1% pancreatic) |
(Selective noncovalent inhibitor) |
96.8% of patients with target lesion reduction; ORR of 31.3%–37.5%. Main TRAEs: G3 neutropenia, anemia. |
| Abstract #4190 |
KRAS G12D Pretreated mPDAC (n = 33 RP2D) |
HRS-4642 + Adebrelimab (Anti-PD-L1) |
Confirmed ORR of 48.5%, DCR 90.9%, and median OS of 11.5 months. Main G3/4 TRAEs: elevated lipase/GGT. |
| Abstract #4191 |
KRAS G12D Pretreated mPDAC (n = 30 RED) |
HRS-4642 + SHR-A2102 (Anti-Nectin-4 ADC) |
Confirmed ORR of 36.7%, DCR 86.7%, and median PFS of 4.1 months. Manageable safety profile. |
| Abstract #3078 |
KRAS G12C Heavily pretreated solid tumors (20% PDAC) |
Darlifarnib (FTI) + Adagrasib (KRAS G12Ci) |
mPDAC cohort (n = 5) achieved 60% ORR and 100% DCR. Manages mTORC1-mediated resistance. |